Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence

Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases: Table 1.

(2016) O. Kanai et al.   ANNALS OF ONCOLOGY

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

(2015) Claire Vanpouille-Box et al.   CANCER RESEARCH

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Local Radiation Therapy in Cancer Immunotherapy

(2015) Sandra Demaria et al.   JAMA Oncology

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH